Is Eledon Pharmaceuticals, Inc. (ELDN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.4% / 30% | 63.3% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 0.4% / 33% | 63.3% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 0.5% / 33% | 79.0% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.4% / 33% | 63.3% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 0.5% / 33% | 79.0% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -35.8% | |
| Return on Assets (ROA) | -30.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$47M |
| Free Cash Flow | -$47M |
| Total Debt | $954,000 |
| Debt-to-Equity | 0.5 |
| Current Ratio | 7.4 |
| Total Assets | $177M |
Price & Trading
| Last Close | $2.96 |
| 50-Day MA | $2.44 |
| 200-Day MA | $2.57 |
| Avg Volume | 953K |
| Beta | 1.0 |
|
52-Week Range
$1.35
| |
About Eledon Pharmaceuticals, Inc. (ELDN)
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Eledon Pharmaceuticals, Inc. (ELDN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Eledon Pharmaceuticals, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Eledon Pharmaceuticals, Inc.'s debt ratio?
Eledon Pharmaceuticals, Inc.'s debt ratio is 0.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.5%.
What are Eledon Pharmaceuticals, Inc.'s key financial metrics?
Eledon Pharmaceuticals, Inc. has a market capitalization of $225M. Return on equity stands at -35.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.